The National Institutes of Health (NIH), the world’s largest biomedical research institute, could bring value in ways you may not be aware of. Its mission includes facilitating economic development.
NIH is open for business – as one of the go-to places for the healthcare industry to work with a thought-leader, overcome a technology or knowledge gap, and get their products to market. Across 27 Institutes and Centers, NIH covers nearly every disease and disorder imaginable – and marketable. It is the largest provider of in-kind support in the world. In addition to drugs NIH also develops devices, diagnostics, wearable and digital health solutions, and software.
NIH is competitive on the business/financial front regarding equity, royalty costs, and overhead rates. NIH needs those in the commercial sector to fulfill its mission of accelerating and promoting economic development. That means working with companies.
In this webinar, NIH experts will discuss the benefits of collaborating with the NIH. They are willing to offer guidance in seeking out these opportunities from a vast range of research projects. This match-making service is offered free of charge to potential partner companies.
Takeaways from the webinar:
- Technology commercialization and economic development is part of NIH’s mission
- Companies, entrepreneurs, and other buy-side stakeholders - not just academia - can partner with the NIH
- Industry partnerships are mutually beneficial for companies and the NIH
- Success stories and partnership examples from how companies have worked with the NIH
- Next steps – points of contact, partnering mechanisms, licensing
Target audience:
Finnish companies, investors, entrepreneurs, and those in economic development. Companies should be in the healthcare sector – requiring regulatory approval. The company's go-to-market strategy is not direct-to-consumer or over-the-counter. Companies do not need to have, or plan to have, any US presence. It does not matter which geography the company plans to penetrate. The webinar is not intended for academic research organizations or service providers.
Agenda
16:00 Welcome and opening words
- Titta Houni, Senior Advisor, Business Finland
16:05 NIH, their role, the collaboration opportunity, sample cases
- Michael Salgaller, Supervisor, National Institutes of Health
- Steven M. Ferguson, Speacial Advisor, National Institutes of Health
16:45 Q&A
The program is subject to change.
Speakers:
Dr. Michael Salgaller is in the technology transfer office of the US National Cancer Institute, National Institutes of Health – where he supervises a unit focused on business development, including establishing collaborations and licensing deals between government and industry. Dr Salgaller has led both early-stage companies and venture capital groups in the private sector. He is the author of the book Biotechnology Entrepreneurship, and teaches an entrepreneurship class at NIH.
Steven M. Ferguson currently serves as Special Advisor at the NIH Office of Technology Transfer where he has worked in licensing & business development since 1990. The biomedical technology transfer program at NIH is one of the world’s largest with a portfolio that includes over 2,000 active licenses with aggregate sales greater than $10B per year that is based upon research that has also generated 44 FDA-approved drugs & vaccines.
